Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% FY25 Revenue at Rs 16,470 Cr; EBITDA at Rs 4,374
As filed · Press Release
What happened
FactRs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% FY25 Revenue at Rs 16,470 Cr; EBITDA at Rs 4,374.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Market Share
WithdrawnThis is a $9 billion opportunity.
It is really up to us to take this market share in a very responsible manner so that we can provide options to patients for a very, very long time.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Looking ahead, we remain focused on the strategic expansion of our differentiated GLP-1 portfolio into new mar (management committed by FY26)
- the focus has always been to see that we have a new product launch either in the US or in Europe every year fr (management committed by FY27)
Evidence
- Biocon Limited has informed the Exchange regarding a press release dated May 08, 2025, titled "Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA atRs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% FY25 Revenue at Rs 16,470 Cr; EBITDA at Rs 4,374Cr; Net Profit at Rs 1,013 Cr".(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q2 FY26
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%